Alzamend Neuro Regains Nasdaq Compliance After Strategic Appeal

Alzamend Neuro ( (ALZN) ) has issued an announcement.

Alzamend Neuro, a biopharmaceutical company targeting Alzheimer’s and other disorders, successfully regained compliance with Nasdaq’s listing standards after a strategic appeal process. Initially facing delisting due to unmet market value requirements, Alzamend demonstrated compliance by securing significant investments and executing a strategic plan. This achievement allows the company to continue its innovative clinical trials, including those in collaboration with Massachusetts General Hospital, aiming to advance treatments for Alzheimer’s and related diseases.

See more insights into ALZN stock on TipRanks’ Stock Analysis page.